Journal of clinical periodontology · 2025
Volume-Stable Collagen Matrix as a Recombinant Human Bone Morphogenetic Protein-2 Carrier for Maxillary Sinus Augmentation: An Experimental In Vivo Study.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kim Chae-Eun, Park Seung-Hyun, Paeng Kyeong-Won, Tavelli Lorenzo, Wu David T, Thoma Daniel S, Jung Ronald E, Jung Ui-Won, Cha Jae-Kook
Аннотация
AIM: To test the hypothesis that a volume-stable collagen matrix (VCMX) can serve as an effective rhBMP-2 carrier for bone regeneration while compensating for the volume instability of absorbable collagen sponge (ACS).
MATERIALS AND METHODS: (i) rhBMP-2 release kinetics from VCMX and ACS were measured over 7 days by enzyme-linked immunosorbent assay. (ii) Bilateral sinus augmentations were performed in 15 rabbits using either VCMX or ACS, with or without rhBMP-2. After 4 weeks, radiographic and histological analyses were conducted.
RESULTS: The overall release patterns between VCMX and ACS did not differ significantly, although VCMX showed a delayed peak release (at 3 h) compared to ACS (at 10 min). Three-dimensional radiographic analysis showed greater volumetric gains in VCMX groups than in ACS groups, regardless of rhBMP-2 loading. Histologically, VCMX/rhBMP-2 group exhibited the largest total augmented area (13.1 ± 2.9 mm2). The use of rhBMP-2 led to significant increases in new bone area for both VCMX (3.9 ± 1.1 vs. 1.6 ± 1.3 mm2, p = 0.003) and ACS (1.8 ± 0.8 vs. 1.0 ± 0.6 mm2, p = 0.035). Notably, the proportion of new bone in the total augmented region was comparable between the VCMX/rhBMP-2 and ACS/rhBMP-2 groups (p > 0.05).
CONCLUSION: rhBMP-2-loaded VCMX enhances bone regeneration in sinus augmentation, suggesting that its volume maintenance may contribute to the improved clinical and radiographic outcomes.
MATERIALS AND METHODS: (i) rhBMP-2 release kinetics from VCMX and ACS were measured over 7 days by enzyme-linked immunosorbent assay. (ii) Bilateral sinus augmentations were performed in 15 rabbits using either VCMX or ACS, with or without rhBMP-2. After 4 weeks, radiographic and histological analyses were conducted.
RESULTS: The overall release patterns between VCMX and ACS did not differ significantly, although VCMX showed a delayed peak release (at 3 h) compared to ACS (at 10 min). Three-dimensional radiographic analysis showed greater volumetric gains in VCMX groups than in ACS groups, regardless of rhBMP-2 loading. Histologically, VCMX/rhBMP-2 group exhibited the largest total augmented area (13.1 ± 2.9 mm2). The use of rhBMP-2 led to significant increases in new bone area for both VCMX (3.9 ± 1.1 vs. 1.6 ± 1.3 mm2, p = 0.003) and ACS (1.8 ± 0.8 vs. 1.0 ± 0.6 mm2, p = 0.035). Notably, the proportion of new bone in the total augmented region was comparable between the VCMX/rhBMP-2 and ACS/rhBMP-2 groups (p > 0.05).
CONCLUSION: rhBMP-2-loaded VCMX enhances bone regeneration in sinus augmentation, suggesting that its volume maintenance may contribute to the improved clinical and radiographic outcomes.